State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Department of Pharmacy, the Affiliated Zhongda Hospital, Southeast University, Nanjing, 210009, People's Republic of China.
J Neuroimmune Pharmacol. 2021 Dec;16(4):835-853. doi: 10.1007/s11481-020-09978-9. Epub 2021 Jan 29.
Increasing studies showed that several anti-platelet drugs turned out to be a promising strategy for inflammatory response. In this study, we investigated the protective efficiency of pretreatment of indobufen or aspirin combined with clopidogrel or ticagrelor (IACT) on cerebral ischemic injury via NF-κB/NLRP3 pathway. Ischemia/reperfusion (I/R) injury was simulated in vivo by middle cerebral artery occlusion/reperfusion (MCAO/R) model, and rats were pretreated with indobufen and aspirin and their combinations with clopidogrel or ticagrelor respectively. The platelet aggregation, cerebral infarct size, water content, neurological impairment and LDH release were measured. The relative expression of inflammasome mediated pyroptosis was determined by ELISA, RT-PCR, Tunel, Immunofluorescence and Western blotting as appropriate. In vitro, I/R injury was simulated in PC12 cells using oxygen glucose deprivation/reperfusion (OGD/R) and Lipopolysaccharide (LPS) to induce pyroptosis. The effect of combinations were significantly greater than MCAO/R group on decreasing the platelet aggregation, infarct size, brain edema, LDH release and neurologic impairment. LPS aggravated I/R-induced PC12 cell injury, which was significantly suppressed by pretreatment of IACT and Bay11-7082. Mechanistically, IACT alleviated transcriptionally encoded IL-1β, IL-18 and NLRP3 via inhibiting nuclear transportation of NF-κB. Importantly, at protein level, NLRP3, Caspase-1, IL-18, IL-1β and GSDMD were significantly decreased in combination groups both in vivo and vitro. IACT reduce inflammasome mediated pyroptosis in MCAO/R rats and OGD/R PC12 cells through inhibiting NF-κB/NLRP3 signaling pathway, which suggests that drug combination is a protective strategy with clinical potential against I/R-induced injury. Graphical abstract.
越来越多的研究表明,几种抗血小板药物在炎症反应中表现出良好的应用前景。在本研究中,我们通过 NF-κB/NLRP3 通路研究了吲哚布芬和阿司匹林预处理联合氯吡格雷或替格瑞洛(IACT)对脑缺血损伤的保护作用。通过大脑中动脉闭塞/再灌注(MCAO/R)模型在体内模拟缺血再灌注(I/R)损伤,分别用吲哚布芬和阿司匹林及其与氯吡格雷或替格瑞洛的组合对大鼠进行预处理。通过血小板聚集、脑梗死面积、水含量、神经功能损伤和 LDH 释放来评估。通过 ELISA、RT-PCR、Tunel、免疫荧光和 Western blot 检测适当的方法来确定炎性体介导的细胞焦亡的相对表达。在体外,通过氧葡萄糖剥夺/再灌注(OGD/R)和脂多糖(LPS)诱导细胞焦亡来模拟 PC12 细胞的 I/R 损伤。与 MCAO/R 组相比,组合用药在降低血小板聚集、梗死面积、脑水肿、LDH 释放和神经功能损伤方面的效果更为显著。LPS 加重了 I/R 诱导的 PC12 细胞损伤,而 IACT 和 Bay11-7082 的预处理则显著抑制了这种损伤。从机制上讲,IACT 通过抑制 NF-κB 的核转运来减轻转录编码的 IL-1β、IL-18 和 NLRP3。重要的是,在体内和体外,联合用药组的 NLRP3、Caspase-1、IL-18、IL-1β 和 GSDMD 的蛋白水平均显著降低。IACT 通过抑制 NF-κB/NLRP3 信号通路,减少 MCAO/R 大鼠和 OGD/R PC12 细胞中的炎性体介导的细胞焦亡,这表明药物联合应用是一种具有临床潜力的针对 I/R 损伤的保护策略。